Hormonal treatment for prostate cancer in Italy. Preliminary data from a survey of the QUABIOS Group

Archivio Italiano di Urologia e Andrologia

Volumn 78, Issue 1, 2006, Pages 15-19

  Prezioso, Domenico ^a,f   Pappagallo, Giovanni L ^b   Guazzoni, Giorgio ^c   Orestano, Fausto ^d   Zattoni, Filiberto ^e  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b PF Calvi Hospital   (Italy)

^c Faculty of Medicine   (Italy)

^d Casa di Cura Orestano   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Adverse events; Hormonal treatment; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; GONADORELIN;

ASTHENIA; CONTROLLED STUDY; DIARRHEA; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MASTALGIA; NAUSEA; ORCHIECTOMY; PROSTATE CANCER; REVIEW; SEXUAL DYSFUNCTION; VOMITING;

AGED; ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; ITALY; MALE; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33646693634     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Debruyne FMJ, Dijkman GA. Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 1995; 28:177
2. Glass JM, Watkin NA. From mutilation to medication: the history of orchidectomy. Br J Urol 1997; 1:293
3. Kirby, R.: Treatment options for early prostate cancer. Urology 1998; 52;948
4. Carroll PR, Kantoff PW, Bak SP, Brown MA, D'Amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Second International Conference on newer approaches to Androgen Deprivation Therapy (ADT) in prostate cancer. Urology 2002; 60:1
5. Lucas MD, Strijdom SC, Berk M, et al. Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer. Scand J Urol Nephrol 1995; 29:497
6. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163:181
7. Shahinian VB, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154
8. Fossa SD, Aass N, Opjordsmoen S. Assessment of quality of life in patients with prostate cancer. Semin Oncol 1994; 21:657
9. Cleary PD, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 1995; 4:207
10. Iversen P. Qualify of life issues relating to endocrine treatment options. Eur Urol Suppl 1999; 36:20
11. Neri R, Kassem N. Biological and clinical properties of antiandrogens. Prog Cancer Res Therapy 1984; 31:507
12. Kirk D, on behalf of the Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 2000; 86:220
13. Schroder FH, Colette L, de Reijke TM, Whelan P. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitiurinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 2000; 82:283